Share
Export Citation
The role of tissue-type plasminogen activator in chronic hepatitis B-related liver cirrhosis
Fadli F.
Gazzetta Medica Italiana Archivio Per Le Scienze Mediche
Q4Abstract
BACKGROUND: Hepatitis B is an important worldwide health matter that frequently leads to cirrhosis and liver cancer, resulting in substantial mortality. Cirrhosis complicates a considerable percentage of cases, causing impaired clotting and potential bleeding. Elevated tissue-type plasminogen activator (tPA) levels, essential in dissolving blood clots, are associated with severe liver conditions. This focused on tPA’s role in chronic hepatitis B patients with liver cirrhosis.METHODS: The period of this prospective observational study was between April and August of 2023. Serum tissue-type plasminogen activators were evaluated in 70 chronic hepatitis B patients, 23 of whom had liver cirrhosis and 47 who did not, using the enzyme-linked immunosorbent assay (ELISA).RESULTS: Compared to individuals without liver cirrhosis, patients with chronic hepatitis B had significantly higher serum tPA levels (P=0.00) and were significantly associated with Fibroscan (Echosens, Paris, France) degree at F4 level. In the multivariate regression study, Child-Turcotte-Pugh (CTP) Class, aspartate aminotransferase (AST), tPA, and serum albumin were independent indicators of risk for liver cirrhosis progression among chronic hepatitis B patients (OR=1.35, 95% CI: 1.09-1.67, P=0.00; OR=1.03, 95% CI: 1.00-1.07, P=0.02; OR=0.04, 95% CI: 0.00-0.87, P=0.04; OR=0.03, 95% CI: 0.00-0.46, P=0.01, accordingly).CONCLUSIONS: According to our findings, blood tPA levels were shown to be higher in chronic hepatitis B virus (HBV) patients with liver cirrhosis, were linked with Fibroscan (Echosens) scores, and could be regarded as possible indicators of liver cirrhosis.